What does science say about CBD (cannabidiol) and Epilepsy?
- We don’t say yes or no. We show what has been studied.
- Working in a lab or in animals does not mean it works in people.
- Don’t stop or change your treatment without talking to your doctor.
What has been studied
- Lab studies (cells)Tests on cells in a dish.Source: PubMed · as of 6 Nov 2026 · Open the search at PubMed11studies
- Animal studiesTests in mice, rats or other animals.Source: PubMed · as of 6 Nov 2026 · Open the search at PubMed110studies
- Studies in peoplePublished studies with human participants.Source: PubMed · as of 6 Nov 2026 · Open the search at PubMed296studies
- Registered trials in peopleTrials entered in a public registry, whatever their result.ClinicalTrials.gov: 10 · as of 6 Nov 2026 · Open the search at ClinicalTrials.govEU CTIS: 1 · as of 6 Nov 2026 · Open the search at EU CTISBy phase:Phase 4 (4)Phase 3 (3)Phase 2 (2)Phase 1/2 (1)No phase (1)By status:Not yet recruiting (5)Running, not recruiting (3)Recruiting (2)Completed (1)Countries (4):United States (4)Italy (2)Netherlands (2)Canada (1)With a linked publication (results): 0 of 11The registries do not tell us here whether results were posted; a linked publication is shown instead.11trials
- Approved treatmentApproved by a medicines regulator for this disease.No
Examples of what we found
The trials
Phase 4
A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex
Not yet recruiting · Canada
ClinicalTrials.gov · NCT06924827Phase 4
A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
Not yet recruiting · United States
ClinicalTrials.gov · NCT07728097No phase
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
Running, not recruiting · Italy
ClinicalTrials.gov · NCT05485831Phase 3
Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach
Recruiting · Netherlands
EU CTIS · 2023-507843-12-01Phase 1/2
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
Not yet recruiting · United States
ClinicalTrials.gov · NCT06738732Phase 2
Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy
Running, not recruiting · Italy
ClinicalTrials.gov · NCT05803434Phase 4
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Running, not recruiting · United States
ClinicalTrials.gov · NCT05044819Phase 4
Epidiolex® for Anxiety in Pediatric Epilepsy
Completed · United States
ClinicalTrials.gov · NCT05324449
Thinking of paying for it? Read this first
- Ask for published results. Stories, thank-you letters and "patients report" are not results. Ask where the results were published.
- Know what you pay for. Ask in writing: what exactly is included, who gets the money, and what happens if you stop.
- Ask your own doctor first. Some products interfere with chemotherapy, radiation or other medicines. Your treating doctor can check this.
- Do not stop standard treatment for it. Do not stop or delay your treatment without talking to your care team.
Other treatments people ask about
- Cannabis and cannabinoids (CBD, THC)Step: Large trials
- Fasting and fasting-mimicking dietStep: Large trials
- High-dose vitamin CStep: Large trials
- IvermectinStep: Large trials
- Ketogenic dietStep: Large trials
- MelatoninStep: Large trials
- MetforminStep: Large trials
- Vitamin DStep: Large trials
- HyperthermiaStep: First trials in people
- StatinsStep: First trials in people
- Curcumin (turmeric)Step: Reports in people
- Dichloroacetate (DCA)Step: Reports in people
- Mistletoe extractStep: Reports in people
Not medical advice. Talk to the care team before changing treatment.